CADL
Candel Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$585.43M
P/E Ratio
—
EPS
$-1.01
Beta
-0.58
52W High
$9.27
52W Low
$4.35
50-Day MA
$6.27
200-Day MA
$5.67
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
43.48
PEG Ratio
—
About Candel Therapeutics Inc
Candel Therapeutics Inc. is a pioneering biotechnology company leveraging oncolytic virus technology to develop targeted therapies that precisely attack cancer cells while preserving surrounding healthy tissue. The company aims to enhance anti-tumor immunity through its diverse pipeline, which addresses several difficult-to-treat malignancies. With a strong intellectual property portfolio and strategic alliances with leading research institutions, Candel is poised to drive significant advancements in cancer treatment, ultimately improving patient outcomes and contributing to the evolution of oncology.
Fundamentals
| Revenue (TTM) | 31,000 |
| Gross Profit (TTM) | $-23.07M |
| EBITDA | $-55.58M |
| Operating Margin | 0.00% |
| Return on Equity | -51.20% |
| Return on Assets | -23.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.88 |
| Price-to-Book | 4.24 |
| Price-to-Sales (TTM) | 436.42 |
| EV/Revenue | 821.98 |
| EV/EBITDA | -0.01 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $73.27M |
| Float | $56.91M |
| % Insiders | 15.79% |
| % Institutions | 59.72% |
Historical Volatility
HV 10-Day
69.09%
HV 20-Day
79.08%
HV 30-Day
99.75%
HV 60-Day
81.24%
HV Rank
98.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($19.62 target)
8
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026